Swedish Orphan Biovitrum launches Willfact® under its distribution agreement with LFB BIOMEDICAMENTS

Stockholm, Sweden, Les Ulis, France - April 8 , 2010 - Swedish Orphan Biovitrum
(STO: BVT) and LFB BIOMEDICAMENTS today announced the launch of Willfact® in
Germany, a new product for treatment of the bleeding disorder von Willebrand
disease. Swedish Orphan Biovitrum and LFB also announced the prolongation of the
current distribution agreement through 2014.

Swedish Orphan Biovitrum will, under the agreement with LFB BIOMEDICAMENTS,
distribute Willfact® in Germany, Sweden, Norway, Iceland, Denmark, Estonia,
Latvia, Lithuania, Czech Republic, Slovakia, Hungary and Bulgaria. A Mutual
Recognition Procedure is planned in the forthcoming months to secure marketing
authorization in the majority of the other countries where Swedish Orphan
Biovitrum has the right to distribute Willfact®.

"The opportunity of making Willfact® available to patients with von Willebrand
disease in Germany and elsewhere will be a valuable contribution to improving
the life of these patients. We look forward to a fruitful and continued
partnership with LFB, as other products of value for rare diseases are also
involved in this partnership and we see Willfact® as an important addition to
our emerging Hemophilia franchise," said Martin Nicklasson, CEO of Swedish
Orphan Biovitrum Group.

"The know-how of Swedish Orphan Biovitrum in hospital care and therapeutic
proteins marketing is a key asset in increasing the availability of our
Willfact® product to the patient community in the selected countries. LFB as a
key European player in bleeding disorders will benefit from this partnership,"
said Pierre-Francois Falcou, Senior International Director of LFB Group.



About Willfact®
Willfact® is a very high purity plasma derived human von Willebrand factor (vWF)
concentrate used to stop and prevent bleeding in severe von Willebrand disease
(vWD) patients. It is produced by LFB and is the only vWF concentrate almost
completely free from Factor VIII, and thereby specifically designed for the
treatment of vWD patients.

Willfact® was approved in Germany in mid-2009, the largest pharmaceutical market
in Europe, by the German authorities (the Paul-Ehrlich-Institute) for the
prevention and treatment of hemorrhage or surgical bleeding in vWD when
Desmopressin (DDAVP) treatment alone is ineffective or contraindicated.
Willfact® is distributed in Germany by Swedish Orphan International GmbH, a
subsidiary of Swedish Orphan Biovitrum.



About von Willebrand Disease
Von Willebrand Disease (vWD) is characterized by a deficiency in the protein von
Willebrand Factor (vWF) that plays a role in primary hemostasis and stabilizes
Factor VIII, an essential blood coagulation factor. This disease requires
extensive diagnostic measures and therapeutic options are available which need
to be adapted to the individual needs of the patients. About one percent of the
population is affected by vWD and equally effects men and women. vWD is thereby
the most frequent inherited bleeding disorder. However, only 52.000 patients are
diagnosed globally. According to the Marketing Research Bureau the vWF market
2006 was 209 MUSD.

vWD is divided in three disease types: Type 1 is characterized by mildly or
moderately reduced vWF levels (60-80% of patients), whereas in Type 3 vWD
patients vWF levels are reduced more dramatically (less than 3% of patients).
Type 2 vWD (20-40% of patients) is characterized by qualitative deficiencies in
the vWF protein, thereby losing important protein functions. For Type 1 - and
many type 2 patients, desmopressin (DDAVP) is the current treatment of choice.
For some Type 1, many Type 2 - and all Type 3 vWD-patients, however, DDAVP
treatment alone is not sufficient or is contraindicated.

All three types of vWD may benefit from a substitution with a plasma-derived
vWF. In Germany, treatment options have been limited to blood plasma
concentrates containing a combination of vWF and Factor VIII. However, in vWD
patients the endogenous Factor VIII synthesis is intact and the deficiency of
Factor VIII is a secondary effect due to the lack or absence of vWF. Therefore a
substitution of Factor VIII is only needed in emergency situations with
significant blood loss. High levels of factor VIII may unnecessarily increase
the risk for thrombosis and thereby stroke.



About Swedish Orphan Biovitrum
On January 14, 2010, Biovitrum AB (publ) completed the acquisition of Swedish
Orphan International Holding AB and created Swedish Orphan Biovitrum - a leading
company focused on treatment of rare diseases.

Swedish Orphan Biovitrum is a Swedish based specialty pharmaceutical company
with an international market presence. The company is focused on providing and
developing orphan and niche specialist pharmaceuticals to patients with high
medical needs. The portfolio consists of about 60 marketed products and an
emerging late stage clinical development pipeline within rare diseases. Swedish
Orphan Biovitrum has pro-forma revenues 2009e of about 2 BSEK and approximately
500 employees. The head office is located in Sweden and the share (STO: BVT) is
listed on NASDAQ OMX Stockholm. For more information please visit
www.biovitrum.com <http://www.biovitrum.com/>.



About LFB Group
LFB BIOMEDICAMENTS is part of LFB, a biopharmaceutical group that develops,
manufactures and markets medicinal products for the treatment of serious and
often rare diseases in several major therapeutic fields, namely Hemostasis,
Immunology and Intensive Care.

LFB Group is the leading manufacturer of plasma-derived medicinal products in
France and 6th worldwide and is also among the leading European companies for
the development of monoclonal antibodies and new-generation proteins based on
biotechnologies. With its strong focus on research, the LFB Group is pursuing a
growth strategy that seeks to extend its activities at international level and
develop innovative therapies.

LFB's 2009 turnover reaches €376 million, of which €76 million were dedicated to
the R&D effort. LFB markets its products in 20 countries and is present in
Germany and the UK since 2007 and in Brazil since 2004. Christian Béchon is
president and CEO of the LFB Group (1700 employees).For more information, please
visit www.lfb.fr/en/home.html <http://www.lfb.fr/en/home.html>.



For more information please contact:

Swedish Orphan Biovitrum:
Kennet Rooth, EVP Marketing & Sales
Phone +46 8 412 98 43
kennet.rooth@swedishorphan.com <mailto:kennet.rooth@swedishorphan.com>

Erik Kinnman, EVP Investor Relations
Phone: +46 73 422 15 40
erik.kinnman@biovitrum.com <mailto:erik.kinnman@biovitrum.com>

Martin Nicklasson, CEO
Phone: +46 8 697 20 00

LFB Group :
Pierre-Francois Falcou, Senior International Director
Phone +33 1 69 82 73 43
falcou@lfb.fr <mailto:falcou@lfb.fr>



Swedish Orphan Biovitrum may be required to disclose the information provided
herein pursuant to the Swedish Securities Markets Act. The information was
provided for public release on April 8, 2010 at 8:30 a.m. CET.





[HUG#1401308]